Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2709-2714

  Horne III, McDonald K ^a   Mayo, Donna Jo ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ACCESS;

EID: 0030859258     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2709     Document Type: Article

References (19)

1. Raad II, Luna M, Khalil S-A M, et al: The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 271:1014-1016, 1994
2. Ruggiero RP, Aisenstein TJ: Central catheter fibrin sleeve -Heparin effect. JPEN 7:270-273, 1983
3. Tschirhart JM, Rao MK: Mechanism and management of persistent withdrawal occlusion. Am Surg 54:326-328, 1988
4. Mayo DJ, Pearson DC: Chemotherapy extravasation: A consequence of fibrin sheath formation around venous access devices. Oncol Nurs Forum 22:675-680, 1995
5. Pasquale MD, Campbell JM, Magnant CM: Groshong versus Hickman catheters. Surg Obstet Gynecol 174:408-410, 1992
6. Hurtubise MR, Bottino JC, Lawson M, et al: Restoring patency of occluded central venous catheters. Arch Surg 115:212-213, 1980
7. Monturo AC, Dickerson RN, Muller JL: Efficacy of thrombolytic therapy for occlusion of long-term catheters. JPEN 14:312-314, 1990
8. Groeger JS, Lucas AB, Coit D: Venous access in the cancer patient. PPO Updates 5:1-14, 1991
9. Zajko AB, Reilly JJ, Bron KM, et al: Low-dose streptokinase for occluded Hickman catheters. AJR 141:1311-1312, 1983
10. Curnow A, Idowu J, Behrens E, et al: Urokinase therapy for silastic catheter-induced intravascular thrombi in infants and children. Arch Surg 120:1237-1240, 1985
11. Kersen C, DiStetano A, Blumenschein G, et al: Treatment of vascular access catheter occlusion with urokinase infusion. Proc Am Assoc Cancer Res 29:228, 1988 (abstr)
12. Bagnall HA, Gomperts E, Atkinson JB: Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children. Pediatrics 83:963-966, 1989
13. Haire WD, Lieberman RP, Lund GB, et al: Obstructed central venous catheters. Restoring function with a 12-hour infusion of low-dose urokinase. Cancer 66:2279-2285, 1990
14. Haire WD, Lieberman RP: Thrombosed central venous catheters: Restoring function with a 6-hour urokinase infusion after failure of bolus urokinase. JPEN 16:129-132, 1992
15. Becker GJ, Rabe FE, Richmond BD, et al: Low-dose fibrinolytic therapy. Radiology 148:663-670, 1983
16. de Bono DP, Simoons ML, Tijssen J, et al: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomized double blind European Cooperative Study Group trial. Br Heart J 67:122-128, 1992
17. Stanislav GV, Fitzgibbons RJ, Bailey RT, et al: Reliability of implantable central venous access devices in patients with cancer. Arch Surg 122:1280-1283, 1987
18. Eastridge BJ, Lefor AT: Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13:233-238, 1995
19. Marder VJ, Sherry S: Thrombolytic therapy: Current status. N Engl J Med 318:1512-1520, 1988